Oct. 8, 2009 (United Press International) -- Baxter International Inc. (NYSE:BAX) of Deerfield, Ill., says it has developed a new skin hydration product for children and infants that works subcutaneously.

The Chicago Tribune said Wednesday the medical product company unveiled its new Hylenex system that operates by allowing intravenous fluids to be administered under the skin instead of through more traditional intravenous therapy.

Healthcare professionals said traditional IV efforts involve finding a patient's vein, occasionally leading to multiple attempts due to vein size or patient factors.

Skin hydration is vital during cold and flu season in the United States as more than two million children visit emergency rooms nationwide each year due to dehydration concerns.

"Hylenex exemplifies Baxter's ongoing commitment to innovation and introducing products that help to improve the treatment experience and overall standard of care -- in this case for parents, patients and caregivers alike," Camille Farhat, general manager of Baxter pharmaceuticals and technologies, said of the company's new product.

The Tribune said Baxter International is hoping for as much as $200 million in annual sales initially for its Hylenex product.